• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于慢性髓性白血病靶向治疗的抗癌药物电化学传感器。

Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia.

作者信息

Dodevska Totka

机构信息

Department of Organic Chemistry and Inorganic Chemistry, University of Food Technologies, Plovdiv, Bulgaria.

出版信息

ADMET DMPK. 2025 Jul 18;13(4):2825. doi: 10.5599/admet.2825. eCollection 2025.

DOI:10.5599/admet.2825
PMID:40786065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12335299/
Abstract

BACKGROUND AND PURPOSE

Treatment of chronic myeloid leukaemia includes targeted therapy with tyrosine kinase inhibitors (TKIs): imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. This review aims to prove that electrochemical sensors provide a reliable alternative to the conventional analytical methods for highly sensitive and cost-effective assay of TKIs in pharmaceutical formulations and biofluids. These platforms have significant advantages in fast detection and portability because they could be designed as miniaturized hand-held devices suitable for real-time point-of-care analysis, providing quick results for enabling personalized therapeutic drug monitoring.

EXPERIMENTAL APPROACH

The paper covers recent developments in substrate materials, various electrode designs, the advantages, and limitations of sensors for TKIs, encompassing both basic and applied research.

KEY RESULTS

This is a pioneering study that provides a general review on emerging trends, technologies, and practical applications of electrochemical sensors for TKIs analysis. The article provides researchers with a clear introduction and concise guide to the design and application of electrochemical sensors in the clinical analysis of TKIs.

CONCLUSION

The review is intended to serve as a valuable resource for researchers in navigating the latest developments in TKIs' electrochemical sensing platforms. The fast response, high sensitivities and satisfactory recoveries obtained in blood serum and urine samples show the potential for application of the proposed electroanalytical systems in clinical analysis and optimization of chemotherapeutic treatments.

摘要

背景与目的

慢性髓性白血病的治疗包括使用酪氨酸激酶抑制剂(TKIs)进行靶向治疗,这些抑制剂有伊马替尼、达沙替尼、尼洛替尼、博舒替尼、波纳替尼和阿西替尼。本综述旨在证明,电化学传感器为药物制剂和生物流体中TKIs的高灵敏度和高性价比检测提供了一种可靠的传统分析方法替代方案。这些平台在快速检测和便携性方面具有显著优势,因为它们可以设计成适合实时即时护理分析的小型手持设备,能够快速得出结果以实现个性化治疗药物监测。

实验方法

本文涵盖了底物材料、各种电极设计、TKIs传感器的优点和局限性等方面的最新进展,包括基础研究和应用研究。

关键结果

这是一项开创性研究,对TKIs分析电化学传感器的新兴趋势、技术和实际应用进行了全面综述。本文为研究人员提供了关于电化学传感器在TKIs临床分析中的设计和应用的清晰介绍及简明指南。

结论

本综述旨在为研究人员提供宝贵资源,以了解TKIs电化学传感平台的最新进展。在血清和尿液样本中获得的快速响应、高灵敏度和令人满意的回收率表明,所提出的电分析系统在临床分析和化疗治疗优化中具有应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/786f1be97d93/ADMET-13-2825-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/c26e958f75d2/ADMET-13-2825-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/29e081e7bf80/ADMET-13-2825-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/94e6cd3e0d67/ADMET-13-2825-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/786f1be97d93/ADMET-13-2825-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/c26e958f75d2/ADMET-13-2825-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/29e081e7bf80/ADMET-13-2825-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/94e6cd3e0d67/ADMET-13-2825-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c7a/12335299/786f1be97d93/ADMET-13-2825-g004.jpg

相似文献

1
Electrochemical sensors for anticancer drugs used in the targeted therapy of chronic myeloid leukaemia.用于慢性髓性白血病靶向治疗的抗癌药物电化学传感器。
ADMET DMPK. 2025 Jul 18;13(4):2825. doi: 10.5599/admet.2825. eCollection 2025.
2
Chronic Myeloid Leukemia: A Review.慢性髓性白血病:综述
JAMA. 2025 May 13;333(18):1618-1629. doi: 10.1001/jama.2025.0220.
3
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.达沙替尼、高剂量伊马替尼和尼洛替尼治疗伊马替尼耐药性慢性髓性白血病:系统评价和经济评估。
Health Technol Assess. 2012;16(23):iii-xiii, 1-137. doi: 10.3310/hta16230.
4
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性髓性白血病:系统评价和经济评估。
Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220.
5
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.达沙替尼、尼洛替尼和标准剂量伊马替尼一线治疗慢性髓性白血病:系统评价和经济分析。
Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420.
6
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial.沃多替尼用于对多线既往治疗耐药或不耐受的费城染色体阳性慢性髓性白血病患者:一项开放标签、多中心、1/2期试验。
Lancet Haematol. 2025 Mar;12(3):e201-e213. doi: 10.1016/S2352-3026(24)00354-5. Epub 2025 Feb 7.
7
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.新型酪氨酸激酶抑制剂与伊马替尼在不同风险组慢性期慢性髓性白血病一线治疗中的疗效比较:八项随机试验的系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30.
8
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.慢性髓性白血病中酪氨酸激酶抑制剂相关血液学不良事件的网络荟萃分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2280-2291. doi: 10.1111/bcp.13933. Epub 2019 May 23.
9
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
10
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.

本文引用的文献

1
Novel Electrochemical Approaches for Anticancer Drug Monitoring: Application of CoS@Nitrogen-Doped Amorphous Porous Carbon Composite in Nilotinib Detection.用于抗癌药物监测的新型电化学方法:CoS@氮掺杂非晶态多孔碳复合材料在尼洛替尼检测中的应用。
ACS Omega. 2024 Dec 31;10(1):261-271. doi: 10.1021/acsomega.4c05505. eCollection 2025 Jan 14.
2
Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection.氧化铈纳米颗粒辅助的慢性髓性白血病检测适配体传感器
ADMET DMPK. 2024 Aug 18;12(4):623-635. doi: 10.5599/admet.2404. eCollection 2024.
3
Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.
ASCIMIB,一种新型的 BCR-ABL1 变构抑制剂,与伊马替尼联合使用时具有协同作用,无论是否存在耐药性。
Pharmacol Res Perspect. 2024 Aug;12(4):e1214. doi: 10.1002/prp2.1214.
4
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.在伴有非典型e19a2 BCR::ABL1转录本和T315I突变的慢性髓性白血病中,使用阿斯科利尼进行三线治疗后实现无治疗缓解。
Leukemia. 2024 Sep;38(9):2037-2040. doi: 10.1038/s41375-024-02327-2. Epub 2024 Jul 4.
5
Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring.用于药代动力学研究和治疗药物监测的生物样品中酪氨酸激酶抑制剂的预处理及分析技术开发
J Pharm Anal. 2024 Apr;14(4):100899. doi: 10.1016/j.jpha.2023.11.006. Epub 2023 Nov 28.
6
An electrochemical sensor based on carbon nanofiber and molecular imprinting strategy for dasatinib recognition.基于碳纳米纤维和分子印迹策略的电化学传感器用于达沙替尼的识别。
Bioelectrochemistry. 2024 Aug;158:108701. doi: 10.1016/j.bioelechem.2024.108701. Epub 2024 Apr 3.
7
Nanomaterials as catalysts for the sensitive and selective determination of diclofenac.纳米材料作为双氯芬酸灵敏选择性测定的催化剂
ADMET DMPK. 2023 Nov 16;12(1):151-165. doi: 10.5599/admet.2116. eCollection 2024.
8
Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.BCR-ABL1 酪氨酸激酶抑制剂的药物警戒研究:FDA 不良事件报告系统的安全性分析。
BMC Pharmacol Toxicol. 2024 Feb 23;25(1):20. doi: 10.1186/s40360-024-00741-x.
9
Engineering of CuMOF-SWCNTs@AuNPs-Based Electrochemical Sensors for Ultrasensitive and Selective Monitoring of Imatinib in Human Serum.基于CuMOF-SWCNTs@AuNPs的电化学传感器的工程设计用于超灵敏和选择性监测人血清中的伊马替尼。
ACS Omega. 2024 Jan 20;9(4):4744-4753. doi: 10.1021/acsomega.3c08002. eCollection 2024 Jan 30.
10
Electrochemical and theoretical studies of the interaction between anticancer drug ponatinib and dsDNA.抗癌药物波纳替尼与双链DNA相互作用的电化学及理论研究
Sci Rep. 2024 Jan 27;14(1):2278. doi: 10.1038/s41598-024-52609-z.